Related Experiment Video
Updated: Jul 12, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale and prothrombotic markers in young stroke patients
Robert Belvís1, Amparo Santamaría, Joan Martí-Fàbregas
1Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 32353rbn@comb.cat
Insights
Patent foramen ovale (PFO) is common in cryptogenic stroke. This study found no increased prothrombotic markers in PFO patients, but large PFOs were linked to antiphospholipid antibodies.
Area of Science:
- Cardiology
- Neurology
- Hematology
Background:
- Patent foramen ovale (PFO) is a common cardiac finding in patients with cryptogenic stroke.
- Understanding the association between PFO and prothrombotic markers is crucial for stroke risk stratification.
Purpose of the Study:
- To investigate the prevalence of specific prothrombotic markers in young cryptogenic stroke patients with and without PFO.
- To explore the relationship between PFO size and prothrombotic markers.
Main Methods:
- Prospective study of 39 cryptogenic stroke patients under 55 years.
- PFO diagnosis using simultaneous transcranial Doppler and transesophageal echocardiography.
- Analysis of antiphospholipid antibodies, protein C/S deficiencies, Factor V Leiden, prothrombin gene mutation, and Factor XII mutation.
Main Results:
- PFO was detected in 43.6% of patients.
- No significant differences in prothrombotic markers were found between PFO and non-PFO groups.
- Antiphospholipid antibodies were more frequent in patients with large PFO.
- Large PFOs were associated with deep venous thrombosis and atrial septal aneurysm.
Conclusions:
- PFO itself is not associated with an increased burden of common prothrombotic markers in young cryptogenic stroke patients.
- Antiphospholipid antibodies may be a specific risk factor associated with large PFOs, potentially increasing thrombotic risk.
Abstract:
Patent foramen ovale (PFO) is more frequent in cryptogenic stroke patients than in the general population. The aim of this study was to determine prothrombotic markers regarding PFO in young cryptogenic stroke patients. We prospectively included consecutive cryptogenic stroke patients younger than 55 years. PFO was diagnosed with simultaneous transcranial Doppler and transesophageal echocardiography. We analyzed the following prothrombotic markers: antiphospholipid antibodies (APS), protein C and protein S deficiencies, factor V Leiden FVG1691A, prothrombin gene mutation PTG20210A and coagulation factor XII mutation FXIIC46T. From June 2005 to July 2006 we studied 39 patients, mean age 44.7 +/- 8.6 years, 48.7% men. PFO was detected in 17 patients (43.6%). We found no differences between PFO and non-PFO patients regarding prothrombotic markers: APS (P = 0.851), protein S deficiency (P = 0.851), protein C deficiency (P = 0.249), FVG1691A (P = 0.202), PTG20210A (P = 0.401) or FXIIC46T (P = 0.966). Female gender was the only variable related to prothrombotic markers, independent of PFO (P = 0.001). The only prothrombotic marker related to PFO size (large PFO) was APS (P = 0.043). Large PFO were also related to deep venous thrombosis (P = 0.040) and atrial septal aneurysm (P = 0.010). PFO patients do not present more prothrombotic markers than non-PFO patients, but APS are more frequent in large PFO.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Hemorrhagic Stroke l: Introduction

